摘要
再灌注治疗（溶栓或介入手术）是心肌梗死最有效的治疗手段,但会引起致命的心肌缺血/再灌注损伤。心肌缺血后采取治疗性浅低温疗法（32~35℃）可有效减少心肌梗死面积,提高ST段抬高型急性心肌梗死患者的远期生存率。治疗性浅低温疗法虽经过大量研究已经在很多方面达成了共识,然而其中的很多细节及其涉及的多种分子生物学机制仍需要进一步研究和完善。本文对心肌缺血/再灌注损伤中治疗性浅低温疗法的研究进展作一简要综述。
Summary Currently, reperfusion therapy （thrombolysis or intervention） has been the most effective treat- ment for acute myocardial infarction , but it can cause fatal myocardial ischemia / reperfusion injury. Studies have shown that taking therapeutic mild hypothermia therapy （32 35℃） after myocardial isehemia can effectively re- duce the area of myocardial infarction and improve long-term survival of STEMI patients. Although therapeutic mild hypothermia therapy has reached a consensus in many ways after a lot of research, but the molecular mecha- nisms involved in its still need further research and improvement. This review summaries the progress of therapeu- tic mild hypothermia therapy in myocardial ischemia / reperfusion injury and its prospects in clinical application.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2015年第2期119-121,共3页
Journal of Clinical Cardiology
基金
国家自然科学基金资助项目(No:81360285)
江西省自然科学基金资助项目(No:20122BAB205003)
关键词
治疗性浅低温疗法
心肌缺血/再灌注
分子机制
心肌保护
therapeutic mild hypothermia therapy
myocardial ischemia / reperfusion injury
molecular mechanisms
myocardial protection
